Claims for Patent: 9,987,229

Summary for Patent: 9,987,229

Title:	Process for preparing a medicament
Abstract:	The present invention provides a process for preparing a particulate medicament that has greater homogeneity and a lower adhesion between the particles of the active ingredient and the carrier. The process comprises the steps of: (a) combining a pharmaceutically active ingredient in the form of an agglomerate of primary particles having an agglomerate particle size such that the agglomerate is capable of passing through a sieve having a mesh of 50-3000 .mu.m with a pharmaceutically acceptable particulate carrier, and (b) mixing the resultant material in a mixer to break up the agglomerate into primary particles dispersed in the pharmaceutically acceptable particulate carrier such that 90% or more of the pharmaceutically active ingredient exists as primary particles having a particle size of 50 .mu.m or less.
Inventor(s):	Zeng; Xian-Ming (London, GB), Tee; Seah Kee (London, GB)
Assignee:	Norton Healthcare Ltd. (London, GB)
Application Number:	15/453,940
Patent Claims:	1. An inhalable medicament prepared by a process comprising the steps of: (a) forming a plurality of loose agglomerates of a pharmaceutically active ingredient by passing the pharmaceutically active ingredient through a sieve having a mesh of 50-3000 .mu.m, wherein the loose agglomerates are not spheronized; (b) combining the plurality of loose agglomerates obtained from step (a) with a pharmaceutically acceptable particulate carrier; and (c) mixing the resultant material from step (b) in a mixer outside of an inhaler to break up the loose agglomerates into primary particles of the pharmaceutically active ingredient and to disperse the primary particles in the pharmaceutically acceptable particulate carrier such that 90% or more of the pharmaceutically active ingredient has a particle size of 50 .mu.m or less to provide the inhalable medicament; wherein the pharmaceutically active ingredient is selected from the group consisting of epinephrine, metaproterenol, terbutaline, albuterol, ipratropium bromide, aminophylline, dyphylline, flunisolide, beclomethasone, salmeterol and any isomers thereof. 2. The inhalable medicament of claim 1, wherein the pharmaceutically acceptable particulate carrier comprises lactose. 3. The inhalable medicament of claim 2, wherein the lactose is alpha-lactose monohydrate. 4. The inhalable medicament of claim 1, wherein the agglomerate particle size is such that the agglomerate is capable of passing through a sieve having a mesh of 250-1000 .mu.m. 5. The inhalable medicament of claim 4, wherein in step (a) the pharmaceutically active ingredient is passed through a sieve having a mesh of 250-1000 .mu.m. 6. The inhalable medicament of claim 1, wherein in step (c), the pharmaceutically active ingredient is dispersed homogenously in the pharmaceutically acceptable particulate carrier such that drug recovery from each of a plurality of samples taken from the medicament has a relative standard deviation from the mean of less than or equal to 5%. 7. A process for preparing a dry powder inhaler containing an inhalable medicament comprising the steps of: (a) forming a plurality of loose agglomerates of a pharmaceutically active ingredient by passing the pharmaceutically active ingredient through a sieve having a mesh of 50-3000 .mu.m, wherein the loose agglomerates are not spheronized; (b) combining the plurality of loose agglomerates obtained from step (a) with a pharmaceutically acceptable particulate carrier; (c) mixing the resultant material from step (b) in a mixer outside of an inhaler to break up the loose agglomerates into primary particles of the pharmaceutically active ingredient and to disperse the primary particles in the pharmaceutically acceptable particulate carrier such that 90% or more of the pharmaceutically active ingredient has a particle size of 50 .mu.m or less to provide the inhalable medicament; and (d) filling the inhalable medicament from step (c) into the reservoir of a dry powder inhaler; wherein the pharmaceutically active ingredient is selected from the group consisting of epinephrine, metaproterenol, terbutaline, albuterol, ipratropium bromide, aminophylline, dyphylline, flunisolide, beclomethasone, salmeterol and any isomers thereof. 8. The process of claim 7, wherein the pharmaceutically acceptable particulate carrier comprises lactose. 9. The process of claim 8, wherein the lactose is alpha-lactose monohydrate. 10. The process of claim 7, wherein the agglomerate particle size is such that the agglomerate is capable of passing through a sieve having a mesh of 250-1000 .mu.m. 11. The process of claim 10, wherein in step (a) the pharmaceutically active ingredient is passed through a sieve having a mesh of 250-1000 .mu.m. 12. The process of claim 7, wherein in step (c), the pharmaceutically active ingredient is dispersed homogenously in the pharmaceutically acceptable particulate carrier such that drug recovery from each of a plurality of samples taken from the medicament has a relative standard deviation from the mean of less than or equal to 5%.